Hospitalization Outcomes of Patients with Type 2 Diabetes Mellitus Complicated with Diabetic Ketoacidosis.

IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Israel Medical Association Journal Pub Date : 2024-10-01
Maly Keler, Pavel Vlasov, Matan Elkan, Shlomit Koren, Ronit Koren
{"title":"Hospitalization Outcomes of Patients with Type 2 Diabetes Mellitus Complicated with Diabetic Ketoacidosis.","authors":"Maly Keler, Pavel Vlasov, Matan Elkan, Shlomit Koren, Ronit Koren","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diabetic ketoacidosis (DKA) poses a significant medical emergency in both type 1 (T1DM) and type 2 diabetes mellitus (T2DM) patients. Recent attention has focused on the emergence of euglycemic DKA associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors.</p><p><strong>Objectives: </strong>To understand the epidemiology and outcomes of DKA, particularly in T2DM patients.</p><p><strong>Methods: </strong>We conducted a retrospective cohort analysis of 204 patients admitted with DKA to Shamir Medical Center (2013-2021). We assessed demographics, clinical characteristics, and outcomes. Patients were stratified by diabetes type and SGLT2 inhibitor treatment status.</p><p><strong>Results: </strong>Among the 204 patients with DKA, 38.2% had T2DM. Patients with T2DM exhibited older age, higher co-morbidity burden, and greater prevalence of microvascular complications compared to T1DM patients. Mortality rates were notably higher among T2DM patients, despite similar DKA severity at presentation, including in-hospital mortality rates of 6.4% vs. 0%, P < 0.05, and 90-day mortality rates of 7.7% vs. 0%, P < 0.05. T2DM was independently associated with adverse hospitalization outcomes, including a composite of rehospitalization, prolonged hospital stays, and mortality (odds ratio 2.68, 95% confidence interval 1.302-5.557). SGLT2 inhibitor treatment did not affect hospitalization outcomes of patients with T2DM.</p><p><strong>Conclusions: </strong>Our findings underscore the importance of recognizing DKA as a substantial complication in diabetic patients, particularly those with T2DM. Vigilance in management, adherence to DKA guidelines, and awareness of triggers such as SGLT2 inhibitors are crucial for improving outcomes in this population.</p>","PeriodicalId":50268,"journal":{"name":"Israel Medical Association Journal","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Israel Medical Association Journal","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Diabetic ketoacidosis (DKA) poses a significant medical emergency in both type 1 (T1DM) and type 2 diabetes mellitus (T2DM) patients. Recent attention has focused on the emergence of euglycemic DKA associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors.

Objectives: To understand the epidemiology and outcomes of DKA, particularly in T2DM patients.

Methods: We conducted a retrospective cohort analysis of 204 patients admitted with DKA to Shamir Medical Center (2013-2021). We assessed demographics, clinical characteristics, and outcomes. Patients were stratified by diabetes type and SGLT2 inhibitor treatment status.

Results: Among the 204 patients with DKA, 38.2% had T2DM. Patients with T2DM exhibited older age, higher co-morbidity burden, and greater prevalence of microvascular complications compared to T1DM patients. Mortality rates were notably higher among T2DM patients, despite similar DKA severity at presentation, including in-hospital mortality rates of 6.4% vs. 0%, P < 0.05, and 90-day mortality rates of 7.7% vs. 0%, P < 0.05. T2DM was independently associated with adverse hospitalization outcomes, including a composite of rehospitalization, prolonged hospital stays, and mortality (odds ratio 2.68, 95% confidence interval 1.302-5.557). SGLT2 inhibitor treatment did not affect hospitalization outcomes of patients with T2DM.

Conclusions: Our findings underscore the importance of recognizing DKA as a substantial complication in diabetic patients, particularly those with T2DM. Vigilance in management, adherence to DKA guidelines, and awareness of triggers such as SGLT2 inhibitors are crucial for improving outcomes in this population.

并发糖尿病酮症酸中毒的 2 型糖尿病患者的住院治疗结果。
背景:糖尿病酮症酸中毒(DKA)是1型糖尿病(T1DM)和2型糖尿病(T2DM)患者的重大急症。最近,人们关注与钠-葡萄糖共转运体-2(SGLT2)抑制剂相关的优生酮症酸中毒的出现:目的:了解 DKA 的流行病学和预后,尤其是 T2DM 患者的情况:我们对沙米尔医疗中心收治的 204 名 DKA 患者(2013-2021 年)进行了回顾性队列分析。我们对人口统计学、临床特征和结果进行了评估。根据糖尿病类型和 SGLT2 抑制剂治疗情况对患者进行分层:在 204 名 DKA 患者中,38.2% 患有 T2DM。与 T1DM 患者相比,T2DM 患者的年龄更大、并发症负担更重、微血管并发症发生率更高。尽管发病时的 DKA 严重程度相似,但 T2DM 患者的死亡率明显更高,其中院内死亡率为 6.4% 对 0%(P < 0.05),90 天死亡率为 7.7% 对 0%(P < 0.05)。T2DM 与不良住院结果(包括再次住院、住院时间延长和死亡率的综合结果)密切相关(几率比 2.68,95% 置信区间 1.302-5.557)。SGLT2抑制剂治疗不会影响T2DM患者的住院预后:我们的研究结果表明,认识到 DKA 是糖尿病患者,尤其是 T2DM 患者的重要并发症非常重要。提高管理警惕性、遵守 DKA 指南以及对 SGLT2 抑制剂等诱发因素的认识对于改善这一人群的预后至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Israel Medical Association Journal
Israel Medical Association Journal 医学-医学:内科
CiteScore
2.20
自引率
12.50%
发文量
54
审稿时长
3-8 weeks
期刊介绍: The Israel Medical Association Journal (IMAJ), representing medical sciences and medicine in Israel, is published in English by the Israel Medical Association. The Israel Medical Association Journal (IMAJ) was initiated in 1999.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信